InvestorsHub Logo
Followers 0
Posts 2
Boards Moderated 0
Alias Born 01/13/2012

Re: Probart post# 4094

Friday, 01/13/2012 1:00:37 PM

Friday, January 13, 2012 1:00:37 PM

Post# of 43835
CelSci got good press coming out of one of the big biotech meetings held this week. News is that the 880 patient Phase III trial is going well, so well that TEVA, one of the marketing and trial partners, requested additional territory for marketing MultiKine when the trial ends. And TEVA has inside information about results, since they are running some of the trials in Israel. That could account for some of the uptick.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News